04.14.15
Johnson & Johnson’s Q1 sales were $17.4 billion, a decrease of 4.1% compared to the first quarter of 2014. Operational results increased 3.1% and the negative impact of currency was 7.2%. Domestic sales increased 5.9% while international sales decreased 12.4%, reflecting operational growth of 0.8% and a negative currency impact of 13.2%, the company said.
Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 5.7%, domestic sales increased 9.1% and international sales increased 3.0%.
"The company delivered strong underlying growth in the first quarter driven by new products and the strength of the core business. Of note is the continued robust growth of the pharmaceutical business and the solid performance of our consumer brands," said Alex Gorsky, chairman and CEO. "I am proud of our global teams who focus every day on delivering innovative solutions to address evolving health care needs."
Worldwide consumer sales of $3.4 billion for the first quarter represented a decrease of 4.7% versus the prior year, consisting of an operational increase of 3.4% and a negative impact from currency of 8.1%. Domestic sales increased 3.8%; international sales decreased 9.7%, which reflected an operational increase of 3.1% and a negative currency impact of 12.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.7%, domestic sales increased 5.1% and international sales increased 4.5%.*
Positive contributors to operational results were sales of Neutrogena and Aveeno as well as Listerine oral care products, plus domestic sales of baby care products.
Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 5.7%, domestic sales increased 9.1% and international sales increased 3.0%.
"The company delivered strong underlying growth in the first quarter driven by new products and the strength of the core business. Of note is the continued robust growth of the pharmaceutical business and the solid performance of our consumer brands," said Alex Gorsky, chairman and CEO. "I am proud of our global teams who focus every day on delivering innovative solutions to address evolving health care needs."
Worldwide consumer sales of $3.4 billion for the first quarter represented a decrease of 4.7% versus the prior year, consisting of an operational increase of 3.4% and a negative impact from currency of 8.1%. Domestic sales increased 3.8%; international sales decreased 9.7%, which reflected an operational increase of 3.1% and a negative currency impact of 12.8%. Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 4.7%, domestic sales increased 5.1% and international sales increased 4.5%.*
Positive contributors to operational results were sales of Neutrogena and Aveeno as well as Listerine oral care products, plus domestic sales of baby care products.